Currently, the therapeutic targets of NAFLD/NASH drugs in clinical trials primarily focus on GLP-1R, SGLT, PPAR, FXR, HSD17B13, TLR, AMPK, THR-β, ACC, and the gut microbiota, among others. This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatohepatitis.